Exatecan derivative for ADC (DXD) is an inhibitor targeting DNA topoisomerase I, belonging to the camptothecin (CPT) class of compounds. DNA topoisomerase I inhibitors currently stand as the most promising ADC payloads, causing DNA damage and cell apoptosis by cleaving single-strand DNA and suppressing the topoisomerase repair mechanism. The new generation DXD-ADC employs DXD as a drug carrier (payload) that effectively determines DXD stability and release efficiency, applicable in plasma/serum pharmacokinetic analysis of ADC drugs, determination of drug binding affinity, analysis of Drug Antibody Ratio (DAR), and evaluation of ADC drug efficacy.
Figure. 1 DXD-the most promising payload for next-generation ADCs 
This tool serves as a core instrument for conducting PK (Pharmacokinetic) analysis of DXD-ADCs and qualitative analysis of coupled DAR values, expediting the R&D process of ADC drugs.
Desirable Characteristics of DXD-ADC
- a highly potent payload (DXD) with a short systemic half-life;
- a cleavable linker designed to be tumor selective which is stable in circulation;
- an average drug-to-antibody ratio (DAR) up to 8 being optimized for each target;
- DXD with more potent inhibitory activity of Topo I than SN-38.
CUSABIO DXD Monoclonal Antibodies
Purity validated to be over 90% through SDS-PAGE.
Anti-DXD antibody activity verified through binding with leading ADC drug DS-8201.
Expert Technical Team
Responsive within 24 hours for any pre-sales or after-sales inquiries.
More: Anti-Payload Antibody DXD: a Highly Potent Tool for ADCs Pharmacokinetic (PK) Analysis!